Comments

Cue Biopharma Stock Price, Quotes and Forecasts

Q: What sector and industry does Cue Biopharma (CUE) operate in?

Cue Biopharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

CUENASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$0.6631

At close: May 27 EDT

$0.6700

0.006901.04%

Pre-Market: 7:53 PM EDT

Cue Biopharma (CUE) Forecast

News Earnings Cue Biopharma (CUE) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Edge Rankings

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings

Cue Biopharma Stock Price, Quotes and Forecasts | NASDAQ:CUE | Benzinga

Explore Cue Biopharma stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for CUE.

Open	-
Close	-
Volume / Avg.	0 / 182.17K
Day Range	- - -
52 Wk Range	0.45 - 1.99
Market Cap	$50.48M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	41
Short Interest	1.15%
Days to Cover	6.31

Recent News

What's Going On With Cue Biopharma Shares Tuesday?

Cue reported 2024 fiscal-year earnings on Monday after the market closed.

Dylan Berman

Cue Biopharma, Inc. Reports Q2 Loss, Tops Revenue Estimates

Cue Biopharma, Inc. (NASDAQ: CUE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.

Zacks

Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24 insurance revenue guidance.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.5

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	-
Close	-
Volume / Avg.	0 / 182.17K
Day Range	- - -
52 Wk Range	0.45 - 1.99
Market Cap	$50.48M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	41
Short Interest	1.15%
Days to Cover	6.31

About Cue Biopharma Inc

Sector

Health Care

Industry

Biotechnology

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and propri...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Cue Biopharma (CUE) stock?

You can purchase shares of Cue Biopharma (NASDAQ:CUE) through any online brokerage.

View our list of the best stock brokerages

Who are Cue Biopharma (CUE) competitors?

Other companies in Cue Biopharma’s space includes: Renovaro (NASDAQ:RENB), Kalaris Therapeutics (NASDAQ:KLRS), Outlook Therapeutics (NASDAQ:OTLK), Fortress Biotech (NASDAQ:FBIO) and Adverum Biotechnologies (NASDAQ:ADVM).

What is the forecast, or price target, for Cue Biopharma (CUE) stock?

Cue Biopharma has a consensus price target of $5.29.

What is the current price for Cue Biopharma (CUE)?

The stock price for Cue Biopharma (NASDAQ: CUE) is $0.67 last updated May 27, 2025 at 7:53 PM EDT.

Does Cue Biopharma (CUE) pay a dividend?

There are no upcoming dividends for Cue Biopharma.

When is Cue Biopharma (NASDAQ:CUE) reporting earnings?

Cue Biopharma’s Q2 earnings are confirmed for Wednesday, August 13, 2025.

Is Cue Biopharma (CUE) going to split?

There is no upcoming split for Cue Biopharma.

What sector and industry does Cue Biopharma (CUE) operate in?

Cue Biopharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.